Rechercher des projets européens

20 projets européens trouvés

Recherche sur 125080 projets européens

 EN COURS 
PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy.With 3.5 million cancer patients in Europe every year, new cancer medicines are eagerly awaited, notably for prostate and ovarian cancer.Systemically applied new immunotherapies are promising, but their toxicity is a hurdle. Vaccination against cancer is safe but rather disappointing: the microenv ...
Voir le projet

 11

 EN COURS 

Molecule-to-man pain network (PAIN-Net)

Date du début: 1 févr. 2017, Date de fin: 31 janv. 2021,

Neuropathic pain affects 5% of the general population and 40% of patients with neurological diseases, and has a key role in the pathophysiology of cancer pain that affects up to 50% of patients in the early disease stage and 30% of survivors, causing an enormous social burden. Treatments are inadequate with less than 50% of patients achieving 50% of pain relief at best, while up to 30% of cancer p ...
Voir le projet

 13

 EN COURS 
Molecular in vitro diagnostics and biomedical research have allowed great progress in personalised medicine but further progress is limited by insufficient guidelines for pre-analytical workflow steps (sample collection, preservation, storage, transport, processing etc.) as well as by insufficient quality assurance of diagnostic practice. This allows using compromised patients’ samples with post c ...
Voir le projet

 21

 TERMINÉ 
"Exposure to secondhand tobacco smoke (SHS) has been classified as a "Group 1" carcinogen (known human carcinogen) by the International Agency for Research on Cancer and has been shown to have adverse health effects on adults and children, including heart disease and respiratory disorders. Electronic cigarettes (e-cigarettes), the most common “electronic nicotine delivery system”, have irrupted i ...
Voir le projet

 11

 TERMINÉ 
"Cancers of the Head and Neck Region (HNC) are the 6th more deadly cancers worldwide: in Europe ~150.000 new cases are detected and ~70.000 patients die every year. The main reasons for high mortality are the fact that the majority of cases are diagnosed in advanced Stage and the intrinsic heterogeneity of such tumors. At present the only adopted treatment decision method is based on TNM (Tumor-ly ...
Voir le projet

 13

 TERMINÉ 
Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predicted in advance. Previous work identified clinical and biological predictors but a major, coordinated approach is needed to validate them so they can be used clinically. The EU has ~17.8 million people living with a prior diagnosis of cancer of whom ~7 million ...
Voir le projet

 15

 TERMINÉ 
Age–related chronic diseases (ArCD) are complex non-linear processes that depends on a large number of interconnected genetic and metabolic pathways which should be tackled with a many faceted preventive strategy. Calorie-dense diet and sedentary lifestyle are responsible of the growing prevalence of metabolic syndrome (MetS), which, together with tobacco, is the major preventable cause of ArCD, m ...
Voir le projet

 1

 TERMINÉ 

Immunostimulatory Agonist antibodies for Cancer Therapy (IACT)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,

"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immun ...
Voir le projet

 11

 TERMINÉ 
Nutrition-related diseases caused a loss of over 56 million years of healthy life of European citizens in 2000. I.Family will make a significant contribution to reduce this burden by studying the interplay and impact of the main drivers of dietary behaviour and food choice. It will take advantage of the unique opportunity to follow-up the large IDEFICS children’s cohort to not only provide added v ...
Voir le projet

 17

 TERMINÉ 

A European Platform for Translational Cancer Research (EUROCANPLATFORM)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Voir le projet

 29

 TERMINÉ 
Sarcomas are rare malignant tumors, with an overall incidence of 6/105/year. Bone and soft tissue connective tissue tumours encompass more than 50 different rare histotypes and more than 150 different molecular subtypes. The incidence of individual rare sarcomas subtypes is often less than 0.5/105/year. Given sarcoma rarity as a group, but even more as individual entities, few prospective clinical ...
Voir le projet

 22

 TERMINÉ 
"The joint institute Fudan University Shanghai Cancer Centre – Institut Mérieux laboratory (FDUSCC-IM), created in May 2010, is conducting ambitious scientific research projects on oncology in China. Its 2 founding partners, Fudan University (China) and Transgene (part of Institut Mérieux, France) wish to increase their translational medical research cooperation with European countries. In a firs ...
Voir le projet

 5

 TERMINÉ 
"EPIC-CVD's overarching goal is to provide clinicians and policy-makers with a menu of evidence-based options for cost-effective individualised risk assessment that enables the EU's increasingly resource-constrained economies to achieve more personalised predictive medicine in harmony with Europe's diverse cultures and healthcare systems.We will achieve this through developing and validating innov ...
Voir le projet

 33

 TERMINÉ 
"Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understan ...
Voir le projet

 11

 TERMINÉ 

Genomic predictors and oncogenic drivers in hepatocellular carcinoma (HEPTROMIC)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,

"Hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers, and is a major health problem. Its incidence is growing and with more than 700,000 annual cases worldwide -50,000 in Europe-, it is the 3rd cause of cancer-related mortality. Most patients are diagnosed at advanced stages with dismal survival rates lower than 1 year, even after sorafenib, the sole systemic therapy availab ...
Voir le projet

 10

 TERMINÉ 
Our interest is to extend the understanding of Jak and STAT signaling in the immunologic processes conditioning the outcome of allogeneic hematopoietic stem cell transplant (allo-HSCT) and to develop new strategies to overcome graft rejection (GR) and graft versus host disease (GVHD).Allo-HSCT is a potentially curative strategy for many patients. GR and GVHD hamper the success of allo-HSCT by con ...
Voir le projet

 1

 TERMINÉ 
The scientific objective of the research carried out in this International Research Staff Exchange Scheme, is the development of a new technology to effectively deliver siRNA to cancer cells by the embedding of a polyplex into the multilayers and multifunctional nanocapsules. We propose to target pro-survival and anti-apoptotic factors in human cancer cells by using siRNA encapsulated into polyele ...
Voir le projet

 3

 TERMINÉ 
In vivo multimodality imaging is a fast growing field in medical research and, although the achievements at clinical level of this diagnostic method are recent, it is already one of the most promising approaches in the diagnosis of diseases in many research addressed medical centres. At present in this area, the USA plays the protagonist role as a result of the amount of resources engaged in the a ...
Voir le projet

 11

 TERMINÉ 
"In vitro diagnostics have allowed a great deal of progress in medicine but are limited by two factors: (a) the lack of guidelines in collection, handling, stabilisation and storage of biosamples which limits the reproducibility of subsequent diagnoses, and (b) its scale is restrained to the cellular level. To address this first point, this IP, SPIDIA, built of clinicians, academics, tool and assa ...
Voir le projet

 17

 TERMINÉ 
The aim of this project is the assembly and the fabrication of a new generation of multifunctional nanostructures for performing combined hyperthermia and controlled drug release, specifically targeted to cancer cells. The “magnetic nanocontainers” we intend to develop can perform at the same time cell recognition, hyperthermia treatment, and, as a consequence of the heat and /or cell environment ...
Voir le projet

 11